

Resource Summary Report

Generated by [RRID](#) on Sep 10, 2026

ONE Study

RRID:SCR_003886

Type: Tool

Proper Citation

ONE Study (RRID:SCR_003886)

Resource Information

URL: <http://www.onestudy.org/>

Proper Citation: ONE Study (RRID:SCR_003886)

Description: Consortium aiming to produce regulatory T cells that are compatible with a kidney transplant patient's immune system, as a measure to suppress the body's natural immune response against a transplanted organ. If successful, this approach will reduce a transplantation patient's life-long dependency on immune suppressing drugs, many of which are often associated with undesirable side effects and can limit the patient's daily routine. The consortium goals are to develop and conduct clinical trials of various immunoregulatory T-cell-based products in organ transplantation recipients, allowing a direct comparison of the safety, clinical practicality and therapeutic efficacy of each cell type. The central focus of the project is to: # Production and manufacture of distinct populations of hematopoietic immunoregulatory T cells # Comparatively study the tolerogenic characteristics of these regulatory cell types # Test these cell therapy products side by side in a clinical trial living donor renal transplant recipients The first workstream will work with different T regulatory cell, tolerogenic DC and suppressive macrophage cell products that are currently in development. In addition to these therapeutics, another goal of this workstream is to develop a cell tracking technology that assesses pharmacodynamics and pharmacokinetics of these cell-based therapies. The second workstream is focused on designing and conducting a cell therapy based clinical trial in renal transplantation, taking into consideration ethics, concurrent immunosuppressive drug use, state-of-the-art immune monitoring, innovative all-in-one data capturing systems, and pharmacovigilance. The goal is to have a comparative evaluation of hematopoietic cell therapy safety in renal transplantation. The third workstream aims to learn more about the specific comparative characteristics of suppressive cell types and to use this knowledge to improve later trial designs and foster novel ideas for new or improved suppressive / tolerogenic cell population.

Abbreviations: ONE Study

Synonyms: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation, The ONE Study - A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation, The ONE Study

Resource Type: consortium, data or information resource, organization portal, portal

Keywords: immune response, organ transplant, kidney, clinical trial, cell therapy, clinical, immune system, tool development, basic research, healthcare, drug development, transplant surgery, immunosuppression, hematopoietic immunoregulatory cell

Funding: European Union FP7

Resource Name: ONE Study

Resource ID: SCR_003886

Alternate IDs: nlx_158215

Record Creation Time: 20220129T080221+0000

Record Last Update: 20260905T132510+0000

Ratings and Alerts

No rating or validation information has been found for ONE Study.

No alerts have been found for ONE Study.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Morali K, et al. (2025) Leveraging current insights on IL-10-producing dendritic cells for developing effective immunotherapeutic approaches. FEBS letters, 599(14), 2025.

Fortunato M, et al. (2021) Regulatory Cell Therapy in Organ Transplantation: Achievements and Open Questions. Frontiers in immunology, 12, 641596.

Jimenez Vera E, et al. (2019) Standardisation of flow cytometry for whole blood immunophenotyping of islet transplant and transplant clinical trial recipients. PloS one, 14(5), e0217163.

Amodio G, et al. (2019) Role of myeloid regulatory cells (MRCs) in maintaining tissue homeostasis and promoting tolerance in autoimmunity, inflammatory disease and transplantation. Cancer immunology, immunotherapy : CII, 68(4), 661.

- Ten Brinke A, et al. (2019) Ways Forward for Tolerance-Inducing Cellular Therapies- an AFACTT Perspective. *Frontiers in immunology*, 10, 181.
- Zahorchak AF, et al. (2018) High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. *Cellular immunology*, 323, 9.
- Peng B, et al. (2018) Regulatory B cells: the cutting edge of immune tolerance in kidney transplantation. *Cell death & disease*, 9(2), 109.
- Biswas M, et al. (2018) Gene Therapy With Regulatory T Cells: A Beneficial Alliance. *Frontiers in immunology*, 9, 554.
- Alikhan MA, et al. (2018) Regulatory T cells in renal disease. *Clinical & translational immunology*, 7(1), e1004.
- Riquelme P, et al. (2018) TIGIT+ iTregs elicited by human regulatory macrophages control T cell immunity. *Nature communications*, 9(1), 2858.
- Mathew JM, et al. (2018) A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants. *Scientific reports*, 8(1), 7428.
- Marín E, et al. (2018) Tolerogenic Dendritic Cells in Solid Organ Transplantation: Where Do We Stand? *Frontiers in immunology*, 9, 274.
- Hutchinson JA, et al. (2018) Predicting Early Viral Control under Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus Using Pretreatment Immunological Markers. *Frontiers in immunology*, 9, 146.
- Passerini L, et al. (2017) Forkhead-Box-P3 Gene Transfer in Human CD4+ T Conventional Cells for the Generation of Stable and Efficient Regulatory T Cells, Suitable for Immune Modulatory Therapy. *Frontiers in immunology*, 8, 1282.
- Pilat N, et al. (2017) Combining Adoptive Treg Transfer with Bone Marrow Transplantation for Transplantation Tolerance. *Current transplantation reports*, 4(4), 253.
- Hu M, et al. (2016) Regulatory T cells in kidney disease and transplantation. *Kidney international*, 90(3), 502.
- Brent L, et al. (2016) Transplantation tolerance--a historical introduction. *Immunology*, 147(3), 267.
- Bartlett ST, et al. (2016) Report from IPITA-TTS Opinion Leaders Meeting on the Future of T-Cell Replacement. *Transplantation*, 100 Suppl 2(Suppl 2), S1.
- Broichhausen C, et al. (2014) In question: the scientific value of preclinical safety pharmacology and toxicology studies with cell-based therapies. *Molecular therapy. Methods & clinical development*, 1, 14026.
- Salisbury EM, et al. (2014) Transplantation tolerance. *Pediatric nephrology (Berlin, Germany)*, 29(12), 2263.